Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Fermin

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
JACC. Heart Failure|January 4, 2024
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE CohortFlorian Rader, Artur Oręziak, Lubna Choudhury, et al.
JACC. Cardiovascular Imaging|September 10, 2024
Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM: Insights From the VALOR-HCM TrialMilind Y Desai, Yuichiro Okushi, Kathy Wolski, et al.
Circulation|May 12, 2025
Correction to: Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results from VALOR-HCMMilind Y Desai, Kathy Wolski, Anjali Owens, et al.
Circulation|November 18, 2024
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCMMilind Y Desai, Kathy Wolski, Anjali Owens, et al.
Circulation. Cardiovascular Imaging|September 2, 2024
Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM TrialMilind Y Desai, Yuichiro Okushi, Andrew Gaballa, et al.
JAMA Cardiology|August 28, 2023
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical TrialMilind Y Desai, Anjali Owens, Kathy Wolski, et al.
Faraday Discussions|November 29, 2016
Reactions at the nanoscale: general discussionThom Hersbach, Julie MacPherson, Olaf Magnussen, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|December 29, 2024
Limited Concordance of Left Ventricular Ejection Fraction and Chamber Dimensions With Automated Assessments in Hypertrophic Cardiomyopathy: A Substudy From VALOR-HCMGary Parizher, Alice Haouzi, Wael A Jaber, et al.
Journal of the American College of Cardiology|September 4, 2024
Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM TrialMilind Y Desai, Anjali Owens, Kathy Wolski, et al.
Faraday Discussions|November 29, 2016
Nanopores: general discussionAndrew Mount, Minkyung Kang, David Fermin, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
JACC. Heart Failure|January 4, 2024
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE CohortFlorian Rader, Artur Oręziak, Lubna Choudhury, et al.
JACC. Cardiovascular Imaging|September 10, 2024
Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM: Insights From the VALOR-HCM TrialMilind Y Desai, Yuichiro Okushi, Kathy Wolski, et al.
Circulation|May 12, 2025
Correction to: Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results from VALOR-HCMMilind Y Desai, Kathy Wolski, Anjali Owens, et al.
Circulation|November 18, 2024
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCMMilind Y Desai, Kathy Wolski, Anjali Owens, et al.
Circulation. Cardiovascular Imaging|September 2, 2024
Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM TrialMilind Y Desai, Yuichiro Okushi, Andrew Gaballa, et al.
JAMA Cardiology|August 28, 2023
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical TrialMilind Y Desai, Anjali Owens, Kathy Wolski, et al.
Faraday Discussions|November 29, 2016
Reactions at the nanoscale: general discussionThom Hersbach, Julie MacPherson, Olaf Magnussen, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|December 29, 2024
Limited Concordance of Left Ventricular Ejection Fraction and Chamber Dimensions With Automated Assessments in Hypertrophic Cardiomyopathy: A Substudy From VALOR-HCMGary Parizher, Alice Haouzi, Wael A Jaber, et al.
Journal of the American College of Cardiology|September 4, 2024
Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM TrialMilind Y Desai, Anjali Owens, Kathy Wolski, et al.
Faraday Discussions|November 29, 2016
Nanopores: general discussionAndrew Mount, Minkyung Kang, David Fermin, et al.
Pageof 3